ABBV/ENTA’s Global Phase-3 Program for ABT-493/ABT-530
[Updated for inclusion of CERTAIN-1/2, EXPEDITION-2, and MAGELLAN-2; and major changes to ENDURANCE-3.]
There are ten phase-3 trials with a total of approximately 2,500 patients at clinical-trial sites in about 30 countries; all of these trials are expected to report data in late 2016 or 1H17.
• CERTAIN-1—245 Japanese patients with any genotype; 8-week and 12-week arms (including an arm for renally-impaired patients); expected completion May 2017: https://www.clinicaltrials.gov/ct2/show/NCT02707952